Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

The effects of differences in pspA alleles and capsular types on the resistance of Streptococcus pneumoniae to killing by apolactoferrin.

Mirza S, Benjamin WH Jr, Coan PA, Hwang SA, Winslett AK, Yother J, Hollingshead SK, Fujihashi K, Briles DE.

Microb Pathog. 2016 Oct;99:209-219. doi: 10.1016/j.micpath.2016.08.029. Epub 2016 Aug 26.

PMID:
27569531
2.

Multivalent Pneumococcal Protein Vaccines Comprising Pneumolysoid with Epitopes/Fragments of CbpA and/or PspA Elicit Strong and Broad Protection.

Chen A, Mann B, Gao G, Heath R, King J, Maissoneuve J, Alderson M, Tate A, Hollingshead SK, Tweten RK, Briles DE, Tuomanen EI, Paton JC.

Clin Vaccine Immunol. 2015 Oct;22(10):1079-89. doi: 10.1128/CVI.00293-15. Epub 2015 Aug 5.

3.

Prediction and characterization of helper T-cell epitopes from pneumococcal surface adhesin A.

Singh R, Gupta P, Sharma PK, Ades EW, Hollingshead SK, Singh S, Lillard JW.

Immunology. 2014 Apr;141(4):514-30. doi: 10.1111/imm.12194.

4.

Phenotypic, genomic, and transcriptional characterization of Streptococcus pneumoniae interacting with human pharyngeal cells.

Kimaro Mlacha SZ, Romero-Steiner S, Hotopp JC, Kumar N, Ishmael N, Riley DR, Farooq U, Creasy TH, Tallon LJ, Liu X, Goldsmith CS, Sampson J, Carlone GM, Hollingshead SK, Scott JA, Tettelin H.

BMC Genomics. 2013 Jun 9;14:383. doi: 10.1186/1471-2164-14-383.

5.

PspA family distribution, antimicrobial resistance and serotype of Streptococcus pneumoniae isolated from upper respiratory tract infections in Japan.

Hotomi M, Togawa A, Kono M, Ikeda Y, Takei S, Hollingshead SK, Briles DE, Suzuki K, Yamanaka N.

PLoS One. 2013;8(3):e58124. doi: 10.1371/journal.pone.0058124. Epub 2013 Mar 6.

6.

The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci in vitro.

Ren B, Li J, Genschmer K, Hollingshead SK, Briles DE.

Clin Vaccine Immunol. 2012 Oct;19(10):1574-82. Epub 2012 Aug 1.

7.

CCL5-independent helper T lymphocyte responses to immuno-dominant pneumococcal surface protein A epitopes.

Singh R, Singh S, Briles DE, Taub DD, Hollingshead SK, Lillard JW Jr.

Vaccine. 2012 Feb 1;30(6):1181-90. doi: 10.1016/j.vaccine.2011.12.020. Epub 2011 Dec 14.

8.

Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.

Bitsaktsis C, Iglesias BV, Li Y, Colino J, Snapper CM, Hollingshead SK, Pham G, Gosselin DR, Gosselin EJ.

Infect Immun. 2012 Mar;80(3):1166-80. doi: 10.1128/IAI.05511-11. Epub 2011 Dec 12.

9.

Maternal immunization with pneumococcal surface protein A protects against pneumococcal infections among derived offspring.

Kono M, Hotomi M, Hollingshead SK, Briles DE, Yamanaka N.

PLoS One. 2011;6(10):e27102. doi: 10.1371/journal.pone.0027102. Epub 2011 Oct 31.

10.

Streptococcus pneumoniae serotype 9A isolates contain diverse mutations to wcjE that result in variable expression of serotype 9V-specific epitope.

Calix JJ, Oliver MB, Sherwood LK, Beall BW, Hollingshead SK, Nahm MH.

J Infect Dis. 2011 Nov 15;204(10):1585-95. doi: 10.1093/infdis/jir593. Epub 2011 Sep 9.

11.

Protection of pneumococcal infection by maternal intranasal immunization with pneumococcal surface protein A.

Hotomi M, Kono M, Hollingshead SK, Briles DE, Yamanaka N.

Adv Otorhinolaryngol. 2011;72:121-5. doi: 10.1159/000324656. Epub 2011 Aug 18.

PMID:
21865708
12.

The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia.

Kataoka K, Fujihashi K, Oma K, Fukuyama Y, Hollingshead SK, Sekine S, Kawabata S, Ito HO, Briles DE, Oishi K.

Infect Immun. 2011 Jul;79(7):2819-28. doi: 10.1128/IAI.01360-10. Epub 2011 May 2.

13.

Serine protease PrtA from Streptococcus pneumoniae plays a role in the killing of S. pneumoniae by apolactoferrin.

Mirza S, Wilson L, Benjamin WH Jr, Novak J, Barnes S, Hollingshead SK, Briles DE.

Infect Immun. 2011 Jun;79(6):2440-50. doi: 10.1128/IAI.00489-10. Epub 2011 Mar 21.

14.

Streptococcus pneumoniae isolates from middle ear fluid and nasopharynx of children with acute otitis media exhibit phase variation.

Arai J, Hotomi M, Hollingshead SK, Ueno Y, Briles DE, Yamanaka N.

J Clin Microbiol. 2011 Apr;49(4):1646-9. doi: 10.1128/JCM.01990-10. Epub 2011 Feb 23.

15.

A combination of Flt3 ligand cDNA and CpG oligodeoxynucleotide as nasal adjuvant elicits protective secretory-IgA immunity to Streptococcus pneumoniae in aged mice.

Fukuyama Y, King JD, Kataoka K, Kobayashi R, Gilbert RS, Hollingshead SK, Briles DE, Fujihashi K.

J Immunol. 2011 Feb 15;186(4):2454-61. doi: 10.4049/jimmunol.1002837. Epub 2011 Jan 17.

16.

Evolution of the capsular gene locus of Streptococcus pneumoniae serogroup 6.

Bratcher PE, Park IH, Oliver MB, Hortal M, Camilli R, Hollingshead SK, Camou T, Nahm MH.

Microbiology. 2011 Jan;157(Pt 1):189-98. doi: 10.1099/mic.0.043901-0. Epub 2010 Oct 7.

17.

Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.

Gwinn WM, Kirwan SM, Wang SH, Ashcraft KA, Sparks NL, Doil CR, Tlusty TG, Casey LS, Hollingshead SK, Briles DE, Dondero RS, Hickey AJ, Foster WM, Staats HF.

Vaccine. 2010 Oct 4;28(42):6901-14. doi: 10.1016/j.vaccine.2010.08.006. Epub 2010 Aug 17. Erratum in: Vaccine. 2011 Mar 24;29(15):2821.

18.

Secretory-IgA antibodies play an important role in the immunity to Streptococcus pneumoniae.

Fukuyama Y, King JD, Kataoka K, Kobayashi R, Gilbert RS, Oishi K, Hollingshead SK, Briles DE, Fujihashi K.

J Immunol. 2010 Aug 1;185(3):1755-62. doi: 10.4049/jimmunol.1000831. Epub 2010 Jun 28.

19.

Helper T cell epitope-mapping reveals MHC-peptide binding affinities that correlate with T helper cell responses to pneumococcal surface protein A.

Singh R, Singh S, Sharma PK, Singh UP, Briles DE, Hollingshead SK, Lillard JW Jr.

PLoS One. 2010 Feb 25;5(2):e9432. doi: 10.1371/journal.pone.0009432.

20.

The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis.

Daniels CC, Coan P, King J, Hale J, Benton KA, Briles DE, Hollingshead SK.

Infect Immun. 2010 May;78(5):2163-72. doi: 10.1128/IAI.01199-09. Epub 2010 Mar 1.

21.

Streptococcus pneumoniae forms surface-attached communities in the middle ear of experimentally infected chinchillas.

Reid SD, Hong W, Dew KE, Winn DR, Pang B, Watt J, Glover DT, Hollingshead SK, Swords WE.

J Infect Dis. 2009 Mar 15;199(6):786-94.

PMID:
19434911
22.

Mucosal vaccination with a multicomponent adenovirus-vectored vaccine protects against Streptococcus pneumoniae infection in the lung.

Arévalo MT, Xu Q, Paton JC, Hollingshead SK, Pichichero ME, Briles DE, Girgis N, Zeng M.

FEMS Immunol Med Microbiol. 2009 Apr;55(3):346-51. doi: 10.1111/j.1574-695X.2008.00518.x.

23.

Production of a unique pneumococcal capsule serotype belonging to serogroup 6.

Bratcher PE, Park IH, Hollingshead SK, Nahm MH.

Microbiology. 2009 Feb;155(Pt 2):576-83. doi: 10.1099/mic.0.024521-0.

24.

PCR-based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 to 2007.

Carvalho Mda G, Pimenta FC, Gertz RE Jr, Joshi HH, Trujillo AA, Keys LE, Findley J, Moura IS, Park IH, Hollingshead SK, Pilishvili T, Whitney CG, Nahm MH, Beall BW; Active Bacterial Core Surveillance Team.

J Clin Microbiol. 2009 Mar;47(3):554-9. doi: 10.1128/JCM.01919-08. Epub 2008 Dec 30.

25.

Antibody to the type 3 capsule facilitates immune adherence of pneumococci to erythrocytes and augments their transfer to macrophages.

Li J, Szalai AJ, Hollingshead SK, Nahm MH, Briles DE.

Infect Immun. 2009 Jan;77(1):464-71. doi: 10.1128/IAI.00892-08. Epub 2008 Nov 10.

26.

Engineering of cysteine residues leads to improved production of a human dipeptidase enzyme in E. coli.

O'Dwyer R, Razzaque R, Hu X, Hollingshead SK, Wall JG.

Appl Biochem Biotechnol. 2009 Oct;159(1):178-90. doi: 10.1007/s12010-008-8379-9. Epub 2008 Oct 17.

PMID:
18931951
27.

Development of antibodies to PspA families 1 and 2 in children after exposure to Streptococcus pneumoniae.

Melin MM, Hollingshead SK, Briles DE, Lahdenkari MI, Kilpi TM, Käyhty HM.

Clin Vaccine Immunol. 2008 Oct;15(10):1529-35. doi: 10.1128/CVI.00181-08. Epub 2008 Aug 27.

28.

Distribution of pneumococcal surface protein A families 1 and 2 among Streptococcus pneumoniae isolates from children in finland who had acute otitis media or were nasopharyngeal carriers.

Melin MM, Hollingshead SK, Briles DE, Hanage WP, Lahdenkari M, Kaijalainen T, Kilpi TM, Käyhty HM.

Clin Vaccine Immunol. 2008 Oct;15(10):1555-63. doi: 10.1128/CVI.00177-08. Epub 2008 Aug 27.

29.

Characterization of a streptococcal cholesterol-dependent cytolysin with a lewis y and b specific lectin domain.

Farrand S, Hotze E, Friese P, Hollingshead SK, Smith DF, Cummings RD, Dale GL, Tweten RK.

Biochemistry. 2008 Jul 8;47(27):7097-107. doi: 10.1021/bi8005835. Epub 2008 Jun 14.

30.

Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsis.

Glover DT, Hollingshead SK, Briles DE.

Infect Immun. 2008 Jun;76(6):2767-76. doi: 10.1128/IAI.01126-07. Epub 2008 Apr 7.

31.

Antibodies to pneumococcal surface protein A families 1 and 2 in serum and saliva of children and the risk of pneumococcal acute otitis media.

Simell B, Melin M, Lahdenkari M, Briles DE, Hollingshead SK, Kilpi TM, Kayhty H.

J Infect Dis. 2007 Nov 15;196(10):1528-36. Epub 2007 Oct 31. Erratum in: J Infect Dis. 2008 Mar 1;197(5):779-80.

PMID:
18008233
32.

PspA and PspC minimize immune adherence and transfer of pneumococci from erythrocytes to macrophages through their effects on complement activation.

Li J, Glover DT, Szalai AJ, Hollingshead SK, Briles DE.

Infect Immun. 2007 Dec;75(12):5877-85. Epub 2007 Oct 8.

33.

Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition.

Darrieux M, Miyaji EN, Ferreira DM, Lopes LM, Lopes AP, Ren B, Briles DE, Hollingshead SK, Leite LC.

Infect Immun. 2007 Dec;75(12):5930-8. Epub 2007 Oct 8.

34.

Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins.

Basset A, Thompson CM, Hollingshead SK, Briles DE, Ades EW, Lipsitch M, Malley R.

Infect Immun. 2007 Nov;75(11):5460-4. Epub 2007 Aug 13.

35.

Genetic basis for the new pneumococcal serotype, 6C.

Park IH, Park S, Hollingshead SK, Nahm MH.

Infect Immun. 2007 Sep;75(9):4482-9. Epub 2007 Jun 18.

36.

Structure of a complex of human lactoferrin N-lobe with pneumococcal surface protein a provides insight into microbial defense mechanism.

Senkovich O, Cook WJ, Mirza S, Hollingshead SK, Protasevich II, Briles DE, Chattopadhyay D.

J Mol Biol. 2007 Jul 20;370(4):701-13. Epub 2007 May 10.

37.

Streptococcus pneumoniae sheds syndecan-1 ectodomains through ZmpC, a metalloproteinase virulence factor.

Chen Y, Hayashida A, Bennett AE, Hollingshead SK, Park PW.

J Biol Chem. 2007 Jan 5;282(1):159-67. Epub 2006 Nov 10.

39.

CCL5 modulates pneumococcal immunity and carriage.

Palaniappan R, Singh S, Singh UP, Singh R, Ades EW, Briles DE, Hollingshead SK, Royal W 3rd, Sampson JS, Stiles JK, Taub DD, Lillard JW Jr.

J Immunol. 2006 Feb 15;176(4):2346-56.

40.

Validation of a multiplex pneumococcal serotyping assay with clinical samples.

Lin J, Kaltoft MS, Brandao AP, Echaniz-Aviles G, Brandileone MC, Hollingshead SK, Benjamin WH, Nahm MH.

J Clin Microbiol. 2006 Feb;44(2):383-8.

41.

Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries.

Hollingshead SK, Baril L, Ferro S, King J, Coan P, Briles DE; Pneumococcal Proteins Epi Study Group.

J Med Microbiol. 2006 Feb;55(Pt 2):215-21.

PMID:
16434715
42.
43.
44.

Relative fitness of fluoroquinolone-resistant Streptococcus pneumoniae.

Johnson CN, Briles DE, Benjamin WH Jr, Hollingshead SK, Waites KB.

Emerg Infect Dis. 2005 Jun;11(6):814-20.

45.
46.

Differential PsaA-, PspA-, PspC-, and PdB-specific immune responses in a mouse model of pneumococcal carriage.

Palaniappan R, Singh S, Singh UP, Sakthivel SK, Ades EW, Briles DE, Hollingshead SK, Paton JC, Sampson JS, Lillard JW Jr.

Infect Immun. 2005 Feb;73(2):1006-13.

47.

Evolutionary genetics of the capsular locus of serogroup 6 pneumococci.

Mavroidi A, Godoy D, Aanensen DM, Robinson DA, Hollingshead SK, Spratt BG.

J Bacteriol. 2004 Dec;186(24):8181-92.

48.

Characterization of antibodies to PspA and PsaA in adults over 50 years of age with invasive pneumococcal disease.

Baril L, Briles DE, Crozier P, King J, Punar M, Hollingshead SK, McCormick JB.

Vaccine. 2004 Dec 21;23(6):789-93.

PMID:
15542203
49.

Lipoprotein PsaA in virulence of Streptococcus pneumoniae: surface accessibility and role in protection from superoxide.

Johnston JW, Myers LE, Ochs MM, Benjamin WH Jr, Briles DE, Hollingshead SK.

Infect Immun. 2004 Oct;72(10):5858-67.

50.

Typing of pneumococcal surface protein A (PspA) in Streptococcus pneumoniae isolated during epidemiological surveillance in Brazil: towards novel pneumococcal protein vaccines.

Brandileone MC, Andrade AL, Teles EM, Zanella RC, Yara TI, Di Fabio JL, Hollingshead SK.

Vaccine. 2004 Sep 28;22(29-30):3890-6.

PMID:
15364436

Supplemental Content

Loading ...
Support Center